Injection Qingkailing Meta-analysis of cerebrovascular disease_0.docVIP

 PAGE \* MERGEFORMAT 15 Injection Qingkailing Meta-analysis of cerebrovascular disease [Abstract] Objective To assess the Qing Kai Ling Injection for the clinical effect of cerebrovascular disease. Methods RevMan5.0 software, published in 1994-2008 on the domestic use of Qing Kai Ling Injection treatment of cerebral vascular diseases, controlled clinical trials Meta analysis of different criteria for inclusion in the sensitivity analysis results. The results were included in efficacy evaluation of 38 clinical controlled trial, using fixed effect model, Qingkailing injection in treatment of cerebral vascular diseases effect the value of OR = 3.26, 95% confidence interval [2.71,3.92]. Conclusion Qingkailing injection on the treatment of cerebrovascular disease compared with the control group, efficacy may be better than the control group, but the quality of randomized controlled trials have yet to be confirmed. [Keywords:] Qing Kai Ling Injection, cerebrovascular disease, Meta analysis Abstract: Objective To evaluate the efficacy of Qingkailing injection for cerebrovascular diseases by systematic review of clinical trials. Methods Meta-analysis was used to evaluate the efficacy of Qingkailing injection on cerebrovascular diseases from 38 articles on clinical trials published from 1994 to 2008 in Chinese journals with the software RevMan5.0. Sensitivity analysis was taken to analyze the results of trails with different inclusion criteria. Results 38 clinical control trails were included for efficacy analysis, a fixed effects model was chosen and the value of odds ratio (OR) was 3.26 with the 95% confidence interval from 2.71 to 3.92. Conclusions Qingkailing injection may have positive effect on cerebrovascular diseases, its efficacy need to be confirmed with high-quality randomized controlled trials. Keywords:: Qingkailing injection, cerebrovascular diseases, Meta-analysis Qingkailing injection in the Cuban side, “Angongniuhuang Pill” made on the